TSHA Q2 2023 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M70.6% margin

Operating Income

-$23M-976.4% margin

Net Income

-$25M-1027.1% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-49.1%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$82M

Total Liabilities

$119M

Stockholders' Equity

-$37M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$23M	-$33M	+29.9%
Net Income	-$25M	-$34M	+27.8%